These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17146105)

  • 1. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
    Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
    J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
    Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ
    J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
    Giles F; Verstovsek S; Faderl S; Vey N; Karp J; Roboz G; Khan KD; Cooper M; Bilgrami SF; Ferrant A; Daenen S; Karsten V; Cahill A; Albitar M; Kantarjian H; O'Brien S; Feldman E
    Leuk Res; 2006 Dec; 30(12):1591-5. PubMed ID: 16574225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloretazine for the treatment of acute myeloid leukemia.
    Vey N; Giles F
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laromustine (cloretazine).
    Vey N; Giles F
    Expert Opin Pharmacother; 2010 Mar; 11(4):657-67. PubMed ID: 20163276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
    Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Should patients over 65 years old with acute myeloid leukemia be treated with myelosuppressive chemotherapy?].
    Spataro V; Cometta A; Glauser MP; Schapira M; Grob JP
    Schweiz Med Wochenschr; 1995 Mar; 125(9):429-32. PubMed ID: 7892571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
    J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
    Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Bolaños-Meade J; Guo C; Gojo I; Karp JE
    Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
    Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M; Petersdorf S; Shami PJ; Yeager AM; Eckert S; Abichandani R; Faderl S
    J Clin Oncol; 2010 Feb; 28(4):549-55. PubMed ID: 20026805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.